ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Bayer and Dr. Reddy's Laboratories side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Bayer×Dr. Reddy's Laboratories×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaBayerDr. Reddy's Laboratories
studies on the registry4,1971,694249
open to participants now298607
phase 3 studies under way200110
reach primary completion within a year168354
programswith a study of their own in two years119+5 named only214

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaBayerDr. Reddy's Laboratories
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
19%

Dr. Reddy's Laboratories: 3 of its 4 programs at phase 1

  1. AUR112phase 1
  2. DRL_ABphase 1
  3. CARD11-BCL10-MALT1 Complex Inhibitor XL114phase 1
75%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%

Dr. Reddy's Laboratories: 1 of its 4 programs at phase 2

  1. CD47 Antagonist AUR103 Calciumphase 2
25%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
00%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
Dr. Reddy's Laboratories2 readouts · 0 phase 3·

Dr. Reddy's Laboratories, Dec ’26: 1 program whose next study reaches primary completion

  1. DRL_ABphase 1 · Dec 29 · NCT07744828

Dr. Reddy's Laboratories, Jan ’27: 1 program whose next study reaches primary completion

  1. AUR112phase 1 · Jan 15 · NCT06755450
·········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Dr. Reddy's Laboratories

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 21 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaBayerDr. Reddy's Laboratories
Neoplasmsall three · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Dr. Reddy's Laboratories in Neoplasms: 1 program

  1. CD47 Antagonist AUR103 Calciumphase 2

Their studies: Dr. Reddy's Laboratories’ studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Prostatic Neoplasms2 of 3 · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

–
Renal Insufficiency, Chronic2 of 3 · compare here

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Bayer in Renal Insufficiency, Chronic: 2 programs

  1. nurandociguatphase 2
  2. finerenoneapproved, new study

Their studies: Bayer’s studies of Renal Insufficiency, Chronic in search

–
Stomach Neoplasms2 of 3 · compare here–

Dr. Reddy's Laboratories in Stomach Neoplasms: 1 program

  1. CD47 Antagonist AUR103 Calciumphase 2

Their studies: Dr. Reddy's Laboratories’ studies of Stomach Neoplasms in search

Carcinoma, Hepatocellular2 of 3 · compare here

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

–
Diabetes Mellitus, Type 22 of 3 · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

–
Heart Failure2 of 3 · compare here

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Bayer in Heart Failure: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Heart Failure in search

–
Colorectal Neoplasms2 of 3 · compare here

AstraZeneca in Colorectal Neoplasms: 2 programs

  1. Actinium-225phase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Bayer in Colorectal Neoplasms: 2 programs

  1. sevabertinibphase 3
  2. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

–
Neoplasm Metastasis2 of 3 · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

–
Amyloidosis2 of 3 · compare here

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

Bayer in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis in search

–
Arthritis, Rheumatoid2 of 3 · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

–

Dr. Reddy's Laboratories in Arthritis, Rheumatoid: 1 program

  1. DRL_ABphase 1

Their studies: Dr. Reddy's Laboratories’ studies of Arthritis, Rheumatoid in search

Show all 21

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Bayer 13 of 21 · Dr. Reddy's Laboratories 2 of 4 programs (44 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).